Agreed. Probably looking at something like $7m NPAT against a bit more than $200m revenue. Much better than where they would have been without Bloomers and still very undervalued but room for improvement.
ACW This biotech stock raised $11M in a risk-off environment. Its Alzheimer's drug could change the game
History-making uranium sample grades and an imminent drill run. Infini Resources is poised to transform in 2025